Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PhRMA study highlights progress made in healthcare
The publication, “The Value of Medicines: Facts and Figures 2006,” compiles facts, trends and data that shows how prescription medicines are helping to improve the quality of healthcare
The publication, “The Value of Medicines: Facts and Figures 2006,” compiles facts, trends and data that shows how prescription medicines are helping to improve the quality of healthcare
This study was cleared to begin following the successful completion of a phase Ia study that confirmed the bio-availability of NV-52 in oral form, and its safety when
Alprox-TD is based on NexMed’s proprietary NexACT drug delivery technology, which the company has also used to develop a number of experimental medicines, including treatments for nail fungus
AB-1001 is designed to deliver a commercially available 5HT3-antagonist through the skin for a continuous period of up to five days, thereby providing the patient with sustained relief
Aggrastat (tirofiban hydrochloride), a glycoprotein (GP) IIb/IIIa inhibitor, is used for the treatment of acute coronary syndromes, including unstable angina and non-Q-wave myocardial infarction. Developed by Merck, Aggrastat
The ongoing IoGen study is being conducted at over 25 active sites across the US. Symbollon is planning to conduct a comprehensive advertising campaign during the remainder of
The study, results of which were published in the New England Journal of Medicine, was conducted in the Intramural Research Program of the US National Institute of Arthritis
The results are published in the journal Antimicrobial Agents and Chemotherapy, in a paper authored by AVI research scientists Dr Bruce Geller and Lucas Tilley. Highlights from the
Pharmorphix provides solid form research services. These services are sold to a large number of pharmaceutical and biotech customers that require information on the solid state of therapeutics
The two-year grant will be utilized for RegeneRx’ phase II clinical trial, which is currently enrolling patients. Epidermolysis bullosa (EB) is a rare, often devastating, genetic disease that